

REMARKS


Justification for the amendments is as follows. The specification has been amended to reflect United States Government support in the invention. The polynucleotide of claims 10-12 is supported in the specification at, for example, page 2, lines 31-32; page 7, lines 9-12 and 20-37; and page 8, lines 1-9. The cell of claims 13-15 is supported in the specification at, for example, page 7, line 13; and page 13, lines 34-36. The method of claim 16 is supported in the specification at, for example, page 7, lines 13-19; page 13, lines 34-37; and page 15, lines 1-10. The conditions and disorders of claims 20-25, and 28-33 are supported throughout the specification, for example, at page 2, line 26 (osteogenesis); page 6, line 17 (wound repair); page 14, line 4 (laminin 5 processing activity); and page 2, line 30, and page 14, lines 21-23 (fibrosis, scarring, keloids, and surgical adhesions). The method of claim 19 is supported in the specification at, for example, page 2, lines 31-34; and page 14, line 32, to page 15, line 4. The method of claim 26 is supported in the specification at, for example, page 6, line 35, to page 7, line 6; and on page 14, lines 8-23.

No new matter is added by any of the above amendments.

CONCLUSION

If there are any questions regarding the present communication or the above-referenced application, please call applicants' attorney.

Respectfully submitted,



Bennett J. Berson
Reg. No. 37,094
Attorney for Applicants
QUARLES & BRADY LLP
P.O. Box 2113
Madison, WI 53701-2113

TEL 608/251-5000
FAX 608/251-9166